Navigation Links
DePuy Announces It Will Stop Selling Metal-On-Metal Hip Implants, Notes Rottenstein Law Group LLP

(PRWEB) May 17, 2013

Johnson & Johnson subsidiary DePuy Orthopaedics announced on May 16 that it will stop sales of metal-on-metal hip replacements. This comes after the company saw the market for the products drop significantly* amid lawsuits and calls for increased regulation,** and after the 2010 recall of the DePuy ASR hip implant. The Rottenstein Law Group LLP, a metal-on-metal hip implant law firm, applauds the decision to remove these products from the market and notes that it maintains a comprehensive website at with information on the metal-on-metal hip products from a variety of companies facing increased scrutiny.

Johnson & Johnson said its decision to stop selling the metal liners in the Ultamet Metal-on-Metal Articulation and Complete Ceramic-on-Metal Acetabular Hip System was because of decreased demand and not because of the safety concerns cited by the FDA regarding metal-on-metal hips or the more than 10,000 lawsuits pending against DePuy over the ASR hip implant system (In re: DePuy Orthopaedics Inc., ASR Hip Implant Products Liability Litigation, MDL-2197 (U.S. District Court for the Northern District of Ohio)), according to a May 16 Bloomberg report. The company will continue to sell its DePuy Pinnacle system, though.

“Although the company has said that it did not make this marketing decision because of lawsuits or regulations, the fact remains that there is a recent marked increase of scrutiny of metal-on-metal hips,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP.

For those who believe their metal-on-metal hip implant has injured them, the Rottenstein Law Group LLP offers an in-depth look at hip replacement settlements for metal-on-metal hip implants manufactured by DePuy, Stryker, Smith & Nephew, Biomet and Wright Medical. Common alleged side effects the firm hears about include metallosis (metal poisoning) and the need for revision surgery. The first trial in the country in Los Angeles resulted in the plaintiff winning an $8.3 million damages award (Kransky v. DePuy; BC456086, Los Angeles Superior Court).

For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.


The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com


Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products
2. DePuy Pinnacle Hip Implant Lawsuit News: Bernstein Liebhard LLP Comments on Johnson & Johnson Decision to Stop Metal-on-Metal Hip Sales
3. DePuy ASR Lawsuit Update: Rottenstein Law Group Comments on Delay of Second Federal Trial
4. DePuy ASR Hip Lawsuit News: Bernstein Liebhard LLP Notes Rescheduling of First Bellwether Trial in Federal DePuy ASR Litigation
5. Alleged DePuy Knee Sleeve Failure Lawsuits Now Being Reviewed by Resource4thePeople Attorneys
6. DePuy ASR Lawsuit Update: Rottenstein Law Group Addresses J&J Motion to Appeal $8.3 Million Verdict
7. DePuy ASR Hip Replacement Lawsuits: Bernstein Liebhard LLP Notes Upcoming Conference in New Jersey DePuy ASR Hip Recall Litigation
8. California Jury Awards Man $8 Million after Injured by Defective DePuy ASR Hip Implant
9. DrugRisk Announces Launch of DePuy Hip Resource Center
10. Ongoing Litigation Over Failed DePuy and Stryker Hip Implants Continue Driving Traffic to Number One Website for Cobalt Chromium Toxicity Information
11. Compensation Justified in DePuy ASR $8.35 Million Verdict
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... Trustify is proud to announce the success of the seventh ... organization dedicated to ending domestic violence. , Trustify and Becky’s Fund have joined forces ... of domestic violence. Trustify is also proud to announce the launch of the company’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... Henderson, ... Tennessee to receive Gigabit Internet through a partnership this year with Aeneas Internet ... Henderson is an attractive destination for entrepreneurs who want to build a business. ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Speech and ... believe that with innovative technologies and under the right circumstances, these practices can ... benefit of a dual-approach to his or her therapeutic sessions, as well as ...
(Date:12/1/2015)... ... 2015 , ... It’s official: Tattoo taboo is a thing of the past. ... Millennials (a whopping one in three aged 18 to 25 is inked). As tattoos ... their ink. In fact, RealSelf , the world’s largest community for learning and ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Contraceptives ... Contraceptives, Male Condoms, Female Condoms, Intrauterine Devices, ... Diaphragms, Contraceptive Sponges, Non-Surgical Permanent Contraception Devices) ... Trends and Forecast 2014 - 2020 ", ... (TMR).The report states that the global contraceptives ...
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... 2015  InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical ... for cardiovascular conditions via the inhalation route, today announced ... Australia . InCarda is planning to undertake ... in the first half of 2016. The ... in Adelaide and Melbourne.  In ...
Breaking Medicine Technology: